The federal cabinet's sub-committee, led by Finance Minister Muhammad Aurangzeb, has approved the pricing of 52 critical medicines, a decision that could significantly reduce costs for patients.

Health Minister Mustafa Kamal emphasized that these medicines, which treat diseases like cancer and diabetes, will become more affordable once final cabinet approval is granted.

The sub-committee, comprising five members including the health minister, categorized all 52 drugs under price-fixation, indicating they are either new to the market or alternatives to existing treatments.Kamal explained that price increases are allowed under two conditions: when production becomes unviable due to rising costs or for new molecules.While the approval is pending final cabinet ratification, the move signals a potential breakthrough in making essential medications accessible.

The decision highlights the government's efforts to balance pharmaceutical costs with public health needs, though challenges remain in ensuring timely production and distribution.

This development could alleviate financial burdens on patients and improve healthcare outcomes, marking a key step in addressing healthcare accessibility in the country.